Bank of America raises target for Gilead Sciences stock to USD 172.00
Published on 10/21/2026 at 10:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGuidance and earnings calendar
- Bank of America set a USD 172.00 target on October 20, 2026.
- Second-quarter revenue reached USD 7.80 billion, up 10.6 percent year over year.
- Gilead Sciences stock trades at EUR 137.66 at 10:34 a.m. CEST at Lang & Schwarz on October 21, 2026, 1.15 percent below the Xetra close of October 20, 2026.
- Gilead Sciences plans to report third-quarter results on October 29, 2026.
Gilead Sciences (ISIN US3755581036) received a higher USD 172.00 price target from Bank of America, up from USD 168.00 in the October 20, 2026 note, as MarketBeat reported. At Lang & Schwarz, the stock was trading at EUR 137.66 on October 21, 2026 at 10:34 a.m. CEST, 1.15 percent below the Xetra close of October 20, 2026.
Three events shape the stock
On August 4, 2026, Gilead reported second-quarter revenue of USD 7.80 billion, up 10.6 percent year over year, while the company posted a GAAP net loss of USD 10.5 billion, according to Markets Insider. On October 7, 2026, Truist Financial lifted its target from USD 150.00 to USD 158.00, according to the same dated analyst coverage carried by MarketBeat. On October 20, 2026, Bank of America raised its target from USD 168.00 to USD 172.00 while maintaining a Buy rating.
What does the HIV outlook mean?
The operating signal is stronger than the GAAP loss suggests. In its second-quarter 2026 call, Gilead said HIV sales rose 12 percent year over year to USD 5.7 billion and raised full-year HIV growth guidance to 9 percent to 10 percent from 8 percent, as Yahoo Finance reported. The same call showed quarterly PrEP sales above USD 1.0 billion and total product sales of USD 7.6 billion, up 8 percent year over year.
When are the next results due?
Gilead is scheduled to report third-quarter 2026 results on October 29, 2026 after the market close, with the conference call at 4:30 p.m. ET, according to the company's investor calendar at Gilead Sciences. The earnings release will test whether the raised HIV outlook and new product launches can offset acquisition-related costs and pressure in cell therapy.
Stock trades below the Xetra close
Gilead Sciences has a market capitalization of EUR 169.9 billion and a 52-week range of EUR 98.96 to EUR 142.80 as of October 21, 2026. The current quote sits EUR 5.14 below that 52-week high, while the next results date gives investors a defined near-term checkpoint.
The stock was trading at EUR 137.66 at Lang & Schwarz on October 21, 2026 at 10:34 a.m. CEST, down 1.15 percent versus the Xetra close of October 20, 2026 at EUR 139.26. The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 21, 2026, 10:34 a.m. CEST): EUR 137.66
- Change versus Xetra close: minus 1.15 percent
- Xetra close (October 20, 2026): EUR 139.26
- Market capitalization: EUR 169.9 billion (as of October 21, 2026)
- 52-week range: EUR 98.96-EUR 142.80 (as of October 21, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
